Commentary: Do we all have Alzheimer’s? Drug makers might want you to think so

This month, the Food and Drug Administration changed the label for the recently approved Alzheimer’s treatment aducanumab — sold under the brand name “Aduhelm” — to specify that the controversial drug made by U.S. biotech company Biogen should be used only by patients with mild dementia or mild cognitive impairment. This should be no bar to widespread use, however, as recent efforts indicate that Biogen may be trying to persuade adults who occasionally misplace their keys that they not only have Mild Cognitive Impairment (MCI), but that MCI is an early form of Alzheimer’s disease.